Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Late phase transfusion after CAR T therapy (Xia et al.)
PMID: 42286658 | Retrospective cohort | n=155 | R/R Multiple Myeloma
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First systematic characterization of late vs. early transfusion as distinct prognostic entities in CAR-T-treated MM; the temporal framing is genuinely new |
| Clinical Relevance | 7 | Large, actionable effect size (OS 10.87 vs 37.87 months); directly informs post-CAR-T monitoring protocols and patient counseling |
| Population Reach | 5 | R/R MM is a narrower indication, but CAR-T use is growing rapidly; findings may generalize to other CAR-T hematologic indications |
| Implementation Speed | 7 | Transfusion monitoring is already embedded in post-CAR-T care; this reframes existing data collection as prognostic — no new infrastructure needed |
| Evidence Strength | 6 | Retrospective, single-center (155 patients); abstract-only reviewed; effect size is striking but external validation absent |
Key quantitative result: Median OS 10.87 vs 37.87 months (P<0.0001); NRM significantly higher (P=0.026) with late transfusion. External validation: None; single-center, post hoc analysis. Main limitation: Retrospective, single-center design; confounding by disease burden and marrow reserve not fully addressable; abstract-only limits full methodological assessment. Equity implications: Findings applicable primarily to patients with access to CAR-T therapy — a resource-intensive treatment largely unavailable in LMICs and underserved US communities. Late transfusion monitoring would benefit patients already within specialized CAR-T centers. Evidence Maturity: Confirmed → Validated (within limitations; requires multicenter replication to be practice-changing)
Article 2 — Dual-target CAR-T cell therapy: ASH 2025 updates (Feng et al.)
PMID: 42286724 | Conference summary/Letter | Mixed preclinical + early clinical
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Logic-gated dual-target CAR-T designs represent a meaningful engineering advance; antigen escape is a recognized clinical problem |
| Clinical Relevance | 5 | Phase 2 CD19/CD22 data referenced, but this is a secondary summary — no direct patient-level data presented; AML dual-target remains preclinical |
| Population Reach | 6 | B-cell malignancies and AML represent large hematologic populations; autoimmune extension broadens reach significantly |
| Implementation Speed | 3 | Manufacturing complexity; most constructs are phase 1–2 at best; regulatory pathway undefined for novel architectures |
| Evidence Strength | 3 | Letter format summarizing conference abstracts; medium classification confidence; no primary data |
Key quantitative result: None extractable from this record. External validation: Conference abstract summaries — indirect; no published trial results in this article. Main limitation: Letter format, no primary data, classification confidence medium, ASH abstracts not peer-reviewed at primary level. Equity implications: Dual-target CAR-T will face even steeper access barriers than single-target products; manufacturing complexity increases cost. Evidence Maturity: Revised → Exploratory (confirmed)
Article 3 — Cardiovascular co-listing on cancer death certificates (Ahmed et al.)
PMID: 42286660 | National cross-sectional surveillance | n=56,014,102
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | PMR framework for cardio-oncology surveillance is a methodological contribution; the CVD-cancer co-mortality signal itself is known, but the temporal trend and leukemia-specific finding add value |
| Clinical Relevance | 4 | Surveillance data informs health system planning and guideline development, but doesn't directly change individual patient care |
| Population Reach | 9 | 56 million death certificates; affects all cancer patients at population level; cardio-oncology is a growing clinical field |
| Implementation Speed | 5 | PMR methodology can be adopted by epidemiologists quickly; clinical workflow change is slower |
| Evidence Strength | 6 | Large national dataset (1999–2020); cross-sectional/ecological design; death certificate data has known coding limitations |
Key quantitative result: CVD co-listed on 28.7% of cancer deaths; leukemia PMR 2.174 in young adults; AAPC 1.69% (ages 55–64, p<0.001). External validation: None specific; uses established CDC death certificate database. Main limitation: Death certificate data subject to miscoding; cross-sectional design cannot establish causality; co-listing ≠ cause of death. Equity implications: Leukemia signal in young adults has equity implications (AML/ALL disproportionately affect certain ethnicities); death certificate data captures population broadly. Evidence Maturity: Confirmed → Validated (epidemiological surveillance level)
Article 4 — 3D Portal Vein Geometry Predicts Post-TIPS Outcomes (Wan et al.)
PMID: 42287031 | Multicenter retrospective cohort | n=579
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | 3D vascular geometry as a preoperative biomarker is genuinely novel; geometry-derived features not previously validated in TIPS |
| Clinical Relevance | 6 | Post-TIPS HE and rebleeding are major clinical problems; C-index improvement from 0.715→0.801 is clinically meaningful for patient selection |
| Population Reach | 4 | Cirrhosis patients undergoing TIPS is a defined but limited population; globally significant in terms of liver disease burden |
| Implementation Speed | 6 | Routine CTA data already collected pre-TIPS; software for 3D geometry extraction is the main barrier |
| Evidence Strength | 7 | Multicenter cohort (579 patients) is the strongest design in this batch; C-index delta well above minimum clinically important difference |
Key quantitative result: C-index 0.801 (HE) and 0.792 (rebleeding) for integrated model vs 0.715/0.686 for clinical model alone. External validation: Multicenter design provides internal geographic validation; no independent external cohort reported. Main limitation: Retrospective; software for 3D PVG extraction not standardized; Chinese centers only — external generalizability uncertain. Equity implications: Routine CTA is widely available in high-income settings; 3D geometry extraction software may not be accessible in resource-limited hepatology programs. Evidence Maturity: Confirmed → Validated
Article 5 — Molecular characteristics of RCC with lymph node metastases (Shu et al.)
PMID: 42287060 | Retrospective observational, NGS | n=52
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | IGF2R, JUN, EPHA5, FH as prognostic markers in lymph-metastatic RCC is novel; "metastatic pool" lymph node concept adds mechanistic framing |
| Clinical Relevance | 4 | Hypothesis-generating; no validated biomarker pathway to clinical actionability yet |
| Population Reach | 4 | RCC with LN metastasis is a specific subgroup; relevant to precision oncology |
| Implementation Speed | 3 | Requires prospective validation before clinical adoption; no DOI available |
| Evidence Strength | 3 | n=52, single-center, medium classification confidence; NGS findings require independent replication |
Key quantitative result: VHL (38%), PBRM1 (22%), SETD2 (20%) mutation rates; IGF2R, JUN, EPHA5, FH associated with poor prognosis (no HR/OR stated in abstract). External validation: None. Main limitation: Very small sample (n=52); single-center; no survival outcomes reported quantitatively; abstract-only. Equity implications: Limited — early-stage discovery applicable broadly in principle but no immediate equity dimension. Evidence Maturity: Confirmed → Exploratory
Article 6 — TyG Index and Kidney Stone Disease meta-analysis (Maleki et al.)
PMID: 42286669 | Systematic review and meta-analysis | n=1,066,215
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | TyG-KSD association builds on prior individual studies; meta-analysis synthesis and dose-response characterization are the new contributions |
| Clinical Relevance | 5 | TyG from routine labs; actionable for cardiometabolic risk counseling; however, KSD management change requires further RCT evidence |
| Population Reach | 7 | Kidney stone disease affects ~10% of adults globally; TyG is calculable from routine metabolic panels in all clinical settings |
| Implementation Speed | 7 | TyG index calculable immediately from existing lab data; PROSPERO-registered meta-analysis lends credibility |
| Evidence Strength | 7 | 14 studies, n>1M, dose-response confirmed, PRISMA 2020 compliant; observational base limits causal inference |
Key quantitative result: OR 1.33 per 1-unit TyG increase (95% CI 1.15–1.54); OR 1.52 highest vs lowest quintile (95% CI 1.26–1.84). External validation: Meta-analysis synthesizes 14 independent cohorts — strong indirect validation. Main limitation: All constituent studies observational; residual confounding; TyG not a direct measure of insulin resistance; geographic/ethnic heterogeneity across studies. Equity implications: TyG index is calculable from routine labs in virtually all healthcare settings — high equity potential; relevant to populations with high metabolic disease burden. Evidence Maturity: Confirmed → Validated
Article 7 — Metabolic Surgery in the GLP-1 Era (Iannelli et al.)
PMID: 42286980 | Commentary/perspective | No primary data
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Surgery vs. GLP-1 comparison is well-trodden; commentary adds framing, not new evidence |
| Clinical Relevance | 5 | The surgery vs. pharmacotherapy decision is highly active clinically; the referenced Nature Medicine 2025 data is relevant |
| Population Reach | 7 | Obesity/T2DM affects hundreds of millions globally; treatment choice decisions affect enormous numbers |
| Implementation Speed | 4 | Commentary itself isn't implementable; referenced underlying data may influence guidelines |
| Evidence Strength | 2 | Commentary only; no primary data; medium classification confidence; abstract only reviewed |
Key quantitative result: None from this article; references external 2025 Nature Medicine comparative data. External validation: N/A — opinion piece. Main limitation: No primary data; potential framing bias; unknown if commentary authors have competing interests. Equity implications: Bariatric surgery access is highly inequitable (cost, geography, insurance); GLP-1 RAs are more widely prescribable but also face access barriers. Commentary does not appear to address equity. Evidence Maturity: Revised → Exploratory (confirmed)
Article 8 — Belantamab Mafodotin BelVd vs SOC ITC (Richter et al.)
PMID: 42286808 | Indirect treatment comparison (ITC) | R/R MM ≥3L
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Belantamab mafodotin re-approval is recent; ITC fills a comparative gap but is not a primary trial |
| Clinical Relevance | 6 | ≥3L R/R MM has high unmet need; positioning BelVd vs. SOC is clinically relevant for treatment selection |
| Population Reach | 4 | Late-line R/R MM is a defined but limited population |
| Implementation Speed | 6 | Belantamab is already FDA-approved (re-approved 2024); this ITC could inform formulary and guideline decisions |
| Evidence Strength | 4 | ITC/NMA methodology is indirect; GSK-sponsored; letter format; no patient-level data; medium classification confidence |
Key quantitative result: Favorable ITC for BelVd vs SOC — specific metrics not reported in abstract/letter. External validation: Based on DREAMM-7 trial data; indirect comparison only. Main limitation: Industry-sponsored; letter format; no direct head-to-head RCT; ITC assumptions unverifiable from abstract. Equity implications: Belantamab mafodotin carries significant ocular toxicity monitoring requirements (ophthalmology access needed) — potential access disparity in under-resourced settings. Evidence Maturity: Confirmed → Validated (within ITC limitations)
Article 9 — Vorasidenib in Post-Transplant IDH2-mutant Cholangiocarcinoma (Altiery De Jesus et al.)
PMID: 42286810 | Case report | n=1
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First reported case of vorasidenib in IDH2-mutant CCA post-transplant; ctDNA monitoring in this setting is novel; rare intersection of indications |
| Clinical Relevance | 5 | High relevance for a very small patient population; off-label use in immunosuppressed setting raises important safety/feasibility questions |
| Population Reach | 2 | IDH2-mutant intrahepatic CCA post-transplant is extremely rare; relative to unmet need in this population, reach is 8 |
| Implementation Speed | 3 | Case report only; requires prospective validation; off-label use |
| Evidence Strength | 2 | Single case; no comparator; medium classification confidence; inherently anecdotal |
Key quantitative result: Durable partial response by RECIST + ctDNA reduction sustained ~1 year. External validation: None. Main limitation: n=1; cannot generalize; immunosuppression may confound response; durability beyond 1 year unknown. Equity implications: CCA is more prevalent in Southeast/East Asia; post-transplant oncology requires highly specialized centers. Limited equity reach. Evidence Maturity (relative to population): Exploratory — but maximally significant for this rare niche
Note: Population Reach scored 2 on absolute scale; relative to affected rare disease population with near-zero options, the unmet need dimension is very high.
Article 10 — Poxvirus Manufacturing Advances (Weber & Wolff)
PMID: 42287073 | Review | Unknown population
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | AI-optimized poxvirus bioprocessing with 2-log yield gains is technically significant |
| Clinical Relevance | 2 | Manufacturing review; no patient outcomes data; indirect clinical pathway |
| Population Reach | 3 | Cancer vaccine/oncolytic space has broad theoretical reach but remains experimental |
| Implementation Speed | 3 | Manufacturing platform change requires significant capital; regulatory burden for novel vectors |
| Evidence Strength | 3 | Review article; unknown species model; medium classification confidence |
Key quantitative result: Up to 2-log (100x) yield increase claimed for new purification platforms. External validation: Review synthesis — not original data. Main limitation: Review only; yield claims not independently validated; species model unclear. Equity implications: Improved manufacturing efficiency could reduce cost and broaden access to cancer vaccines — speculative but meaningful. Evidence Maturity: Confirmed → Exploratory
Article 11 — Omega-6/3 Ratio, BMI, and Depression (Naderlou et al.)
PMID: 42286783 | Cross-sectional | n=440
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Omega-3/depression association is well-established; the OR magnitude (9.94 for omega-6/3 ratio) is striking but likely inflated by design |
| Clinical Relevance | 3 | Cross-sectional, small n, dietary recall subject to error; not ready for clinical application |
| Population Reach | 5 | Depression is globally ubiquitous; dietary modification is broadly accessible |
| Implementation Speed | 4 | Dietary advice is low-barrier but this study doesn't justify clinical change |
| Evidence Strength | 3 | Cross-sectional, n=440, single geographic/demographic group, medium classification confidence |
Key quantitative result: OR 0.34 for omega-3 intake vs depression; OR 9.94 for highest vs lowest omega-6/3 quintile. External validation: None; ORs of this magnitude in cross-sectional dietary studies typically do not replicate at full strength. Main limitation: Cross-sectional; small n; homogeneous population (Iranian university students); OR 9.94 is almost certainly an overestimate due to confounding. Equity implications: Dietary interventions are in principle accessible across socioeconomic strata, but omega-3 sources (fish, supplements) carry cost barriers. Evidence Maturity: Confirmed → Exploratory
Article 12 — Limits of Viability Review (Stanojević et al.)
PMID: 42287114 | Review | Periviable infants globally
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Reframing viability limits as health-system constructs rather than biological thresholds is conceptually important, though not entirely new in the literature |
| Clinical Relevance | 6 | Directly relevant to neonatology practice and policy in both HIC and LMIC settings |
| Population Reach | 7 | Periviable birth affects populations globally; equity framing amplifies reach into underserved settings |
| Implementation Speed | 3 | System-level change required; policy and resource allocation timelines are long |
| Evidence Strength | 4 | Review without meta-analytic synthesis; medium classification confidence; abstract only |
Key quantitative result: No primary quantitative data — framing/synthesis review. External validation: N/A — review. Main limitation: Review format; no new primary data; systemic change barriers are substantial. Equity implications: Explicitly centered on HIC/LMIC disparities — this is the primary contribution of the article. Maximally relevant to global health equity. Evidence Maturity: Confirmed → Exploratory
Article 13 — Australian MRI-Linac Program Review (Barton et al.)
PMID: 42287017 | Retrospective research program review
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Documents past program milestones; AI image enhancement outputs are novel in aggregate, but no single new finding |
| Clinical Relevance | 3 | Historical program review; no new clinical trial data reported |
| Population Reach | 4 | Radiotherapy is broadly applicable to cancer patients; MRI-Linac is high-end technology |
| Implementation Speed | 3 | MRI-Linac systems are expensive and limited to major centers; technology diffusion is slow |
| Evidence Strength | 3 | Program retrospective; no patient outcome data; medium classification confidence |
Key quantitative result: 120+ papers, 25 PhDs, >AUD 27M funding — programmatic metrics, not clinical outcomes. External validation: N/A — historical review. Main limitation: No patient outcome data; retrospective program summary only. Equity implications: MRI-Linac technology is capital-intensive and geographically concentrated; significant equity gap between major cancer centers and regional/LMIC settings. Evidence Maturity: Confirmed → Exploratory
PHASE 3 — Ranking
Composite Impact Score Calculation
Weights: Clinical Relevance 30% | Population Reach 25% | Scientific Novelty 20% | Implementation Speed 15% | Evidence Strength 10%
| # | Article (PMID) | Clin Rel (×0.30) | Pop Reach (×0.25) | Sci Nov (×0.20) | Impl Speed (×0.15) | Evid Str (×0.10) | Composite | Triage Score | Flag |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Late transfusion & CAR-T MM (42286658) | 7×0.30=2.10 | 5×0.25=1.25 | 7×0.20=1.40 | 7×0.15=1.05 | 6×0.10=0.60 | 6.40 | 7 | 🟠 |
| 2 | TyG Index & Kidney Stones (42286669) | 5×0.30=1.50 | 7×0.25=1.75 | 5×0.20=1.00 | 7×0.15=1.05 | 7×0.10=0.70 | 6.00 | 5 | 🟢 |
| 3 | 3D Portal Vein Geometry / TIPS (42287031) | 6×0.30=1.80 | 4×0.25=1.00 | 7×0.20=1.40 | 6×0.15=0.90 | 7×0.10=0.70 | 5.80 | 5 | 🟢 |
| 4 | CVD co-listing on cancer deaths (42286660) | 4×0.30=1.20 | 9×0.25=2.25 | 6×0.20=1.20 | 5×0.15=0.75 | 6×0.10=0.60 | 6.00 | 5 | ⬜ |
| 5 | Limits of Viability (42287114) | 6×0.30=1.80 | 7×0.25=1.75 | 5×0.20=1.00 | 3×0.15=0.45 | 4×0.10=0.40 | 5.40 | 4 | 🟡 |
| 6 | Dual-target CAR-T / ASH 2025 (42286724) | 5×0.30=1.50 | 6×0.25=1.50 | 7×0.20=1.40 | 3×0.15=0.45 | 3×0.10=0.30 | 5.15 | 6 | 🟠 |
| 7 | Belantamab BelVd ITC (42286808) | 6×0.30=1.80 | 4×0.25=1.00 | 4×0.20=0.80 | 6×0.15=0.90 | 4×0.10=0.40 | 4.90 | 4 | ⬜ |
| 8 | Vorasidenib in IDH2-mutant CCA (42286810) | 5×0.30=1.50 | 2×0.25=0.50 | 8×0.20=1.60 | 3×0.15=0.45 | 2×0.10=0.20 | 4.25 | 4 | ⚪ |
| 9 | RCC lymph node NGS (42287060) | 4×0.30=1.20 | 4×0.25=1.00 | 6×0.20=1.20 | 3×0.15=0.45 | 3×0.10=0.30 | 4.15 | 5 | ⚪ |
| 10 | Metabolic Surgery vs GLP-1 commentary (42286980) | 5×0.30=1.50 | 7×0.25=1.75 | 3×0.20=0.60 | 4×0.15=0.60 | 2×0.10=0.20 | 4.65 | 5 | ⬜ |
| 11 | Omega-6/3 & Depression (42286783) | 3×0.30=0.90 | 5×0.25=1.25 | 4×0.20=0.80 | 4×0.15=0.60 | 3×0.10=0.30 | 3.85 | 4 | ⬜ |
| 12 | Poxvirus manufacturing review (42287073) | 2×0.30=0.60 | 3×0.25=0.75 | 5×0.20=1.00 | 3×0.15=0.45 | 3×0.10=0.30 | 3.10 | 4 | ⬜ |
| 13 | MRI-Linac program review (42287017) | 3×0.30=0.90 | 4×0.25=1.00 | 4×0.20=0.80 | 3×0.15=0.45 | 3×0.10=0.30 | 3.45 | 4 | ⬜ |
Tie-breaker applied: Articles 2 and 4 both scored 6.00. Article 2 (TyG/KSD) ranks higher on Evidence Strength (7 vs 6) and Implementation Speed (7 vs 5).
Final Ranked Table
| Rank | Article | Impact Score | Triage Score | Clin Rel | Pop Reach | Sci Nov | Impl Speed | Evid Str | Study Design | Flag |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Late transfusion & CAR-T MM (42286658) | 6.40 | 7 | 7 | 5 | 7 | 7 | 6 | Retrospective cohort | 🟠 |
| 2 | TyG Index & Kidney Stones (42286669) | 6.00 | 5 | 5 | 7 | 5 | 7 | 7 | SR + meta-analysis | 🟢 |
| 3 | CVD co-listing on cancer deaths (42286660) | 6.00 | 5 | 4 | 9 | 6 | 5 | 6 | National surveillance | ⬜ |
| 4 | 3D Portal Vein Geometry / TIPS (42287031) | 5.80 | 5 | 6 | 4 | 7 | 6 | 7 | Multicenter retro cohort | 🟢 |
| 5 | Limits of Viability (42287114) | 5.40 | 4 | 6 | 7 | 5 | 3 | 4 | Review | 🟡 |
| 6 | Dual-target CAR-T / ASH 2025 (42286724) | 5.15 | 6 | 5 | 6 | 7 | 3 | 3 | Conference summary/Letter | 🟠 |
| 7 | Belantamab BelVd ITC (42286808) | 4.90 | 4 | 6 | 4 | 4 | 6 | 4 | ITC/NMA | ⬜ |
| 8 | Metabolic Surgery vs GLP-1 (42286980) | 4.65 | 5 | 5 | 7 | 3 | 4 | 2 | Commentary | ⬜ |
| 9 | Vorasidenib in IDH2-mutant CCA (42286810) | 4.25 | 4 | 5 | 2 | 8 | 3 | 2 | Case report | ⚪ |
| 10 | RCC lymph node NGS (42287060) | 4.15 | 5 | 4 | 4 | 6 | 3 | 3 | Retro observational, NGS | ⚪ |
| 11 | Omega-6/3 & Depression (42286783) | 3.85 | 4 | 3 | 5 | 4 | 4 | 3 | Cross-sectional | ⬜ |
| 12 | MRI-Linac program review (42287017) | 3.45 | 4 | 3 | 4 | 4 | 3 | 3 | Program review | ⬜ |
| 13 | Poxvirus manufacturing review (42287073) | 3.10 | 4 | 2 | 3 | 5 | 3 | 3 | Review | ⬜ |
Rank Justification Summaries
Rank 1 — Late transfusion & CAR-T MM (42286658): This retrospective cohort earns the top position by combining the largest effect size in the batch (3.5-fold OS difference), genuine scientific novelty in temporally differentiating early from late transfusion dependence, and immediate implementability — monitoring transfusion dates post-CAR-T requires no new tools or infrastructure. The single-center retrospective design prevents a higher score, but the finding is directly actionable for CAR-T programs tracking treatment-related mortality.
Why it matters: Late transfusion dependence after CAR-T may be the first simple, routinely-collected biomarker to stratify non-relapse mortality risk in myeloma patients — and it costs nothing to measure.
Rank 2 — TyG Index & Kidney Stones (42286669): A million-patient meta-analysis with confirmed dose-response and PROSPERO registration delivers the strongest evidence base in this batch. TyG is calculable from labs already ordered in cardiometabolic workups, making this a genuinely near-zero-cost add-on to metabolic risk counseling. Its placement at #2 rather than #1 reflects a more incremental advance on established metabolic-urologic associations.
Why it matters: A triglyceride and a fasting glucose can now point toward kidney stone risk — bringing metabolic surveillance into nephrology without adding a single new test.
Rank 3 — CVD co-listing on cancer deaths (42286660): The sheer scale (56 million records) and 22-year temporal trend give this national surveillance study exceptional population reach. The leukemia-specific cardiovascular signal in young adults is actionable for cardio-oncology program development. Ranked third rather than second because its cross-sectional death-certificate design limits causal inference and direct clinical application is more diffuse.
Why it matters: Nearly one in three cancer deaths has cardiovascular disease on the certificate — and the trend is getting worse. Cardio-oncology is no longer a subspecialty luxury; it's a population health imperative.
Rank 4 — 3D Portal Vein Geometry / TIPS (42287031): The strongest individual study design in this batch (multicenter, n=579, C-index delta of 0.086–0.106) earns a top-four finish despite being off the primary watchlist. The fact that no new imaging is required — only computational processing of existing pre-procedure CTA — makes implementation realistically near-term for centers with biomedical engineering support.
Why it matters: A vein's shape on a CT scan could tell interventional radiologists which cirrhosis patients face the highest risk of brain complications after TIPS — before they even enter the procedure room.
Rank 5 — Limits of Viability (42287114): The equity framing and global reach of this review elevate it above several higher-scored articles in primary research terms. The reframing of viability limits as health-system constructs rather than biological absolutes carries policy weight in both HIC neonatology guidelines and LMIC resource allocation debates. Evidence Strength cap from review format prevents higher placement.
Why it matters: Where you are born should not determine whether you survive being born early — this review names that inequity plainly and calls the field to account.
Notes on Inter-Article Tension
There is a moderate framing tension between the metabolic surgery commentary (Article 7) and the broader GLP-1 enthusiasm across the cardiometabolic literature. The commentary argues surgery delivers superior long-term outcomes citing a 2025 Nature Medicine study, but this claim cannot be evaluated here given the abstract-only/commentary format. Readers should note this is an expert perspective, not a primary comparative trial, and that GLP-1 RA vs. surgery comparative evidence is still evolving.